Important Notices

Dexcom, Inc. announced the planned discontinuation of the Dexcom G6 Continuous Glucose Monitoring (CGM) System effective July 1, 2026.

On April 20, 2026, and April 22, 2026, Huons Co. Ltd. initiated voluntary recalls of lidocaine HCl Injection, USP, and bupivacaine HCl in dextrose Injection for all lots.

On April 6, 2026, B. Braun Medical initiated a voluntary recall of specific batches of sterile water for injection, 70% dextrose injection, 0.9% sodium chloride irrigation and Lactated Ringer’s irrigation.

On March 17, 2026, Fresenius Kabi USA, LLC initiated a voluntary user level recall of select lots of 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, and 5% Dextrose Injection, USP supplied in single dose freeflex® bags.

On March 12, 2026, Insulet Corporation initiated a voluntary medical device correction of certain Omnipod® 5 Pods.

On March 9, 2026, Ipsen initiated a voluntary withdrawal of Tazverik® (tazemetostat) oral tablets from the US market, effective immediately, for all approved indications.

On March 3, 2026, Cardinal Health issued a voluntary recall of select lots of Webcol™ Large Alcohol Prep Pads

On Feb. 26, 2026, the FDA issued a class I recall for multiple lots of Accord BioPharma’s Udenyca® (pegfilgrastim cbqv) injection, 6mg/0.6mL single dose prefilled syringes.

Summary: On Feb. 6, 2026, Trividia Health initiated an Urgent Medical Device Correction for TRUE METRIX® Blood Glucose Monitoring Systems

Trividia Health, Inc. has issued an Urgent Medical Device Correction to notify affected customers that all TRUE METRIX, TRUE METRIX AIR, and TRUE METRIX GO Self-Monitoring and TRUE METRIX PRO Professional Monitoring Blood Glucose Systems have updated use instructions.